期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 58, 期 4, 页码 604-629出版社
ELSEVIER
DOI: 10.1016/j.addr.2006.03.002
关键词
thrombosis; myointimal hyperplasia (IH); gene delivery; endothelialization; endothelial cell (EC); vascular smooth muscle cell (SMC); extracellular matrix (ECM)
资金
- NHLBI NIH HHS [F32 HL078151, F32 HL078151-01, F32 HL078151-02, R01 HL041272, F32 HL074594, R01-HL41272] Funding Source: Medline
Atherosclerotic cardiovascular disease is a leading cause of death worldwide. Despite recent improvements in medical, operative, and endovascular treatments, the number of interventions performed annually continues to increase. Unfortunately, the durability of these interventions is limited acutely by thrombotic complications and later by myointimal hyperplasia followed by progression of atherosclerotic disease over time. Despite improving medical management of patients with atherosclerotic disease, these complications appear to be persisting. Cardiovascular gene therapy has the potential to make significant clinical inroads to limit these complications. This article will review the technical aspects of cardiovascular gene therapy; its application for promoting a functional endothelium, smooth muscle cell growth inhibition, therapeutic angiogenesis, tissue engineered vascular conduits, and discuss the current status of various applicable clinical trials. (c) 2006 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据